Report : South and Central America Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)
Human Segment has the Largest Share of Source in the South & Central America Monoclonal Antibodies Market during 2021–2028
According to our latest study on “South & Central America Monoclonal Antibodies Market Forecast to 2028 – COVID-19 Impact and Analysis – by Source, Production Method, Indication, Application, and End User,” the market is projected to reach US$ 10,847.3 million by 2028 from US$ 5,584.2 million in 2021; it is expected to grow at a CAGR of 9.9% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising prevalence of cancer and other chronic diseases, mABs uptake proves to be effective during pandemic outbreaks. However, low awareness, accessibility, and high cost is expected to restrict the market growth during the forecast period.
According to the NCBI report, monoclonal antibodies (mABs) have been considered as an innovative technology for the treatment of some types of cancer, as they possess the capability of targeting and selectively killing tumor cells. For example, there was a retrospective analysis conducted based on consultation of the Brazilian Health Regulatory Agency (Anvisa) where these mABs were characterized according to the target antigen, type of antibody, year of registration, therapeutic indications, and applicant. For records, in August 2021, Anvisa announced granting of emergency use authorization (EUA) for Celltrion’s “Regdanvimab (CT-P59)” for treating adults with mild-to-moderate COVID-19 and who do not require supplemental oxygen and are at higher risk of progression to severe COVID. As Brazil had the highest number of confirmed cases from COVID-19 in South and Central America with an average 35,000 cases per day and since the beginning of pandemic, at least 1 in 10 residents have been infected a total of 20,249,176 reported severe cases. Therefore, Celltrion’s monoclonal antibody-based product significantly reduces the risk of COVID-19 related hospitalization and deaths by 72% for patients at higher risk of progression to severe COVID-19 and 70% of all patients. Therefore, amid COVID-19 pandemic, monoclonal antibodies witnessed highest ever adoption in South and Central America regional market.
Based on source, the Monoclonal Antibodies (mAbs) market is segmented into human, humanized, chimeric, and murine. In 2020, the human segment accounted for the highest share, moreover the same segment is expected to grow in the forecast period.
Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., AstraZeneca, Bayer AG, and Bristol-Myers Squibb Company are among the leading companies in the South & Central America monoclonal antibodies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for monoclonal antibodies market is segmented into source, production method, indication, application, and end user. Based on source, the South & Central America monoclonal antibodies market is segmented into human, humanized, chimeric, murine. Based on production method, the monoclonal antibodies market is segmented into in-vitro, in-vivo. Based on indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, others. Based on application, the monoclonal antibodies market is segmented into therapeutic applications, diagnostic applications, research applications. Based on end user, the monoclonal antibodies market is segmented into hospitals, research institutes, others. Geographically, the monoclonal antibodies market is segmented into South & Central America (Brazil, Argentina, Rest of South & Central America).
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org